SciBase lands another customer in the US
The announced partnership is with Seraly Dermatology in Pittsburgh, Pennsylvania. The customer will integrate several Nevisense systems into their skin cancer detection workflow. According to Seraly Dermatology’s website, they have a single location with a staff of 5, so the client seems to be small. Still, each customer win is a sign that the market response to Nevisense remains good and that the product continues to be well positioned.
SciBase mentioned in the press release that they are expanding to a new market. We assume Seraly Dermatology was their first customer in Pennsylvania, which could indicate that insurance coverage for Nevisense diagnostics in the state is on a positive trend. Our revenue growth estimates for Scibase assume steady customer wins, so this deal will not cause any changes to our revenue forecasts.
Login required
This content is only available for logged in users
Scibase Holding
SciBase Holding is a medical technology company. The Group specializes in the management of cancer diagnostics, mainly focused on the treatment and detection of various melanomas. The company has developed an electric handheld probe that analyzes the measurement signal to detect specific changes in the body's skin tissue. The head office is located in Stockholm.
Read more on company pageKey Estimate Figures21.08.
2023 | 24e | 25e | |
---|---|---|---|
Revenue | 23.2 | 29.6 | 45.8 |
growth-% | 29.94 % | 27.36 % | 54.68 % |
EBIT (adj.) | -53.9 | -57.8 | -48.7 |
EBIT-% (adj.) | -232.04 % | -195.19 % | -106.25 % |
EPS (adj.) | -0.50 | -0.30 | -0.22 |
Dividend | 0.00 | 0.00 | 0.00 |
Dividend % | |||
P/E (adj.) | - | - | - |
EV/EBITDA | - | - | - |